# Zilucoplan for Severe gMG Exacerbations

> **NCT07215949** · PHASE3 · RECRUITING · sponsor: **Miriam Freimer** · enrollment: 15 (estimated)

## Conditions studied

- Generalized Myasthenia Gravis (gMG)

## Interventions

- **DRUG:** Zilucoplan®

## Key facts

- **NCT ID:** NCT07215949
- **Lead sponsor:** Miriam Freimer
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-20
- **Primary completion:** 2027-12-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07215949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07215949, "Zilucoplan for Severe gMG Exacerbations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07215949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*